Palliative Oxaliplatin-based Chemotherapy After Exposure to Oxaliplatin in the Adjuvant Setting for Colon Cancer

Overview

Journal J Gastrointest Oncol

Date 2015 Oct 22

PMID 26487941

Citations 3

Authors

Renata DAlpino Peixoto

Aalok Kumar

Howard John Lim

Affiliations

Soon will be listed here.

Abstract

Background: Little is known regarding the efficacy of oxaliplatin-based chemotherapy for metastatic colon cancer patients who have already received adjuvant oxaliplatin-based chemotherapy.

Methods: We retrospectively reviewed 22 consecutive patients who developed recurrence after adjuvant oxaliplatin-based chemotherapy for stage III colon cancer and received another course of oxaliplatin-based chemotherapy for their metastatic disease. The main endpoint was progression-free survival (PFS).

Results: A total of 635 patients received oxaliplatin-based chemotherapy for stage III colon cancer at the British Columbia Cancer Agency from 2006 to 2011. A total of 176 patients recurred, 22 (12.5%) of whom were re-exposed to oxaliplatin in the metastatic scenario. Oxaliplatin in combination with fluoropyrimidine was given as first, second and third line in in 3 (13.6%), 14 (63.6%), and 5 (22.7%) patients respectively. Median time from the last cycle of adjuvant oxaliplatin-based chemotherapy to the first cycle of palliative oxaliplatin-based chemotherapy was 44.3 months. Median PFS and overall survival (OS) were 3.3 (95% CI, 1.4-5.1) and 10.0 months (95% CI, 5.3-14.6), respectively. There was no difference in PFS for patients re-exposed to oxaliplatin less than 36 months compared to longer (3.6 versus 3.1 months, P=0.793, HR =0.88).

Conclusions: In this population-based study, only a small proportion of pts who recurred after oxaliplatin-based adjuvant therapy received oxaliplatin in the metastatic setting. Re-exposure of oxaliplatin in combination with fluoropyrimidine is associated with only modest PFS benefit. Larger studies evaluating the role of oxaliplatin re-exposure are needed.

Citing Articles

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.

Tasci E, Oyan B, Sonmez O, Mutlu A, Atci M, Sakin A BMC Cancer. 2024; 24(1):16.

PMID: 38166764 PMC: 10763265. DOI: 10.1186/s12885-023-11783-5.

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer.

Bellio H, Bertaut A, Hervieu A, Zanetta S, Hennequin A, Vincent J Cancers (Basel). 2021; 13(21).

PMID: 34771635 PMC: 8582415. DOI: 10.3390/cancers13215472.

Chemotherapy re-challenge response rate in metastatic colorectal cancer.

Chambers A, Frick J, Tanner N, Gerkin R, Kundranda M, Dragovich T J Gastrointest Oncol. 2018; 9(4):679-686.

PMID: 30151264 PMC: 6087874. DOI: 10.21037/jgo.2018.04.08.

References

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Porschen R, Arkenau H, Kubicka S, Greil R, Seufferlein T, Freier W . Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007; 25(27):4217-23. DOI: 10.1200/JCO.2006.09.2684. View

Bilchik A, Hoon D, Saha S, Turner R, Wiese D, DiNome M . Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg. 2007; 246(4):568-75. DOI: 10.1097/SLA.0b013e318155a9c7. View

Goldberg R, Fleming T, Tangen C, MOERTEL C, Macdonald J, Haller D . Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998; 129(1):27-35. DOI: 10.7326/0003-4819-129-1-199807010-00007. View

Shirota Y, Stoehlmacher J, Brabender J, Xiong Y, Uetake H, Danenberg K . ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001; 19(23):4298-304. DOI: 10.1200/JCO.2001.19.23.4298. View

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

Fong Y, Fortner J, Sun R, Brennan M, Blumgart L . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230(3):309-18; discussion 318-21. PMC: 1420876. DOI: 10.1097/00000658-199909000-00004. View

Edge S, Compton C . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. DOI: 10.1245/s10434-010-0985-4. View

Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19):3109-16. DOI: 10.1200/JCO.2008.20.6771. View

10.

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

11.

Compton C, Fielding L, Burgart L, Conley B, Cooper H, Hamilton S . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7):979-94. DOI: 10.5858/2000-124-0979-PFICC. View

12.

Scheithauer W, Rosen H, Kornek G, Sebesta C, Depisch D . Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993; 306(6880):752-5. PMC: 1677246. DOI: 10.1136/bmj.306.6880.752. View

13.

Twelves C, Wong A, Nowacki M, Abt M, Burris 3rd H, Carrato A . Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005; 352(26):2696-704. DOI: 10.1056/NEJMoa043116. View

14.

. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995; 345(8955):939-44. View

15.

Tepper J, OConnell M, Hollis D, Niedzwiecki D, Cooke E, Mayer R . Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol. 2003; 21(19):3623-8. DOI: 10.1200/JCO.2003.03.018. View

16.

Moreau L, Rajan R, Thirlwell M, Alcindor T . Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Anticancer Res. 2013; 33(4):1765-8. View

17.

Kuebler J, Wieand H, OConnell M, Smith R, Colangelo L, Yothers G . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25(16):2198-204. DOI: 10.1200/JCO.2006.08.2974. View

18.

Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G . Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004; 22(15):3120-5. DOI: 10.1200/JCO.2004.05.195. View

19.

Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N . Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005; 23(22):4866-75. DOI: 10.1200/JCO.2005.07.113. View

20.

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M . Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Ann Oncol. 2012; 23(9):2313-2318. DOI: 10.1093/annonc/mdr623. View